KT-253
KT253-AL-101
Phase 1 small_molecule completed
Quick answer
KT-253 for Myeloid Malignancies is a Phase 1 program (small_molecule) at Kymera Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kymera Therapeutics
- Indication
- Myeloid Malignancies
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed